摘要
目的探讨11C-蛋氨酸(MET)PET/CT显像对脑胶质瘤的应用价值。方法2例正常对照者、2例脑胶质瘤初诊患者和23例脑胶质瘤术后患者行11C—MET PET/CT显像;25例患者中有17例同时行18F-脱氧葡萄糖(FDG)PET/CT显像。临床随访时间3-17个月。结果4例脑胶质瘤术后无肿瘤残余或复发者11C—MET显像为阴性,其中3例同时行18F—FDG显像也为阴性。2例胶质瘤Ⅱ级初诊者和19例脑胶质瘤术后残余、复发者中,20例11C—MET显像阳性(肿瘤/灰质、肿瘤/白质比值分别为2.02±0.96、3,01±1.79),其中14例同时行18F—FDG显像中12例为阳性。11C—MET显像所见病灶远较18F-FDG显像清晰。14例患者11C-MET、18F—FDG显像的肿瘤/灰质、肿瘤/白质比值分别为2.15±1.16比0.97±0.43(P<0.01)、3.31±2.16比1.90±0.67(P<0.05)。结论11C—MET对脑胶质瘤的显像、定位优于18F—FDG。
Objective To study the clinical value of ^11C-methionine （MET） PET/CT imaging in brain glioma. Methods 27 eases were studied including 2 glioma, 23 operated glioma and 2 healthy volunteers, ^11C-MET PET/CT was performed in all eases but ^18F-fluorodeoxyglueose （FDG） PET/CT in only 17 eases. Follow-up period was within 3 - 17 months. Results ^11C-MET was negative in 4 eases and ^18F-FDG negative in 3 eases in group without remnant or recurrent tumor after operation. In 2 eases of initial glioma and 19 eases with remnant or recurrent tumor group, ^11C-MET imaging was positive in 20 eases, tumor/gray matter ratio and tumor/white matter ratio were 2.02 ±0. 96, 3. 01 ± 1.79, respectively, among them 14 eases also with ^18F-FDG imaging showed positive in 12 eases. Lesions showed by ^11C-MET were far more clear than that of ^18F-FDG. Also tumor/gray matter ratio and the tumor/white matter ratio of ^11C-MET imaging were significantly higher than ^18F-FDG （ 2.15 ± 1.16 vs 0. 97 ±0. 43, P 〈 0. 01 ; 3.31±2.16 vs 1.90 ± 0. 67, P 〈 0. 05 ）. Conclusion ^11C-MET PET/CT is superior to ^18F-FDG PET/CT in the diagnosis and lo- calization of brain glioma.
出处
《中华核医学杂志》
CAS
CSCD
北大核心
2005年第5期286-287,i0003,共3页
Chinese Journal of Nuclear Medicine
基金
广东省科研基金资助项目(A2001381)
